LB Pharmaceuticals Inc develops novel therapies for neuropsychiatric diseases, led by LB-102, an oral investigational small molecule and benzamide antipsychotic candidate for schizophrenia, bipolar depression and adjunctive major depressive disorder. Company news frequently centers on LB-102 clinical data, peer-reviewed publications, medical-conference presentations and trial-program updates across schizophrenia and mood-disorder indications.
Other recurring updates include financial results, capital-raising activity, board and executive appointments, Nasdaq inducement grants and healthcare-conference participation. These announcements frame the company's single-segment biopharmaceutical model around clinical development, financing needs and governance as it advances LB-102.
LB Pharmaceuticals (Nasdaq: LBRX) appointed Robert Lenz, M.D., Ph.D. to its Board of Directors on March 9, 2026. Dr. Lenz brings over 20 years of neuroscience R&D leadership, including senior roles at Neumora Therapeutics and Amgen, and a track record overseeing drug development through regulatory approval.
The appointment is positioned to support advancement of LB-102 into late-stage clinical development across multiple neuropsychiatric indications.
LB Pharmaceuticals (Nasdaq: LBRX) announced management will present at two investor events in March 2026: the Leerink 2026 Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET and the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 2:30 p.m. ET.
A live webcast and archived replay will be available in the Investors > Events section of the company website at https://lbpharma.us/.
LB Pharmaceuticals (Nasdaq: LBRX) granted an inducement equity award to new General Counsel Dr. Minako Pazdera on February 10, 2026 under the Nasdaq Listing Rule 5635(c)(4) exception.
Dr. Pazdera received options to buy 140,000 shares, with a 10-year term, $24.22 exercise price (closing price on grant date) and four-year vesting (25% after one year, then monthly).
LB Pharmaceuticals (Nasdaq: LBRX) entered a securities purchase agreement to sell 3,306,571 shares of common stock and pre-funded warrants to purchase up to 1,417,107 shares at $21.17 per share (pre-funded warrant price $21.1699), anticipating approximately $100.0 million gross proceeds.
The private placement is expected to close on or about February 6, 2026, includes major institutional investors, and names Leerink Partners, Piper Sandler and Stifel as placement agents. Proceeds are intended to fund a Phase 2 trial of LB-102 in major depressive disorder and for working capital; resale registration rights were agreed with investors.
LB Pharmaceuticals (Nasdaq: LBRX) initiated a randomized, double-blind Phase 2 ILLUMINATE-1 trial of oral LB-102 in bipolar 1 depression on Jan 26, 2026. The two-arm, six-week outpatient study will randomize ~320 patients 1:1 to LB-102 (pooled 25 mg or 50 mg once daily) or placebo across ~30 U.S. sites. The primary endpoint is MADRS-10 at week 6 with a primary analysis pooling doses vs placebo. Secondary measures include MADRS-6, CGI-BP, cognition, and anhedonia. Topline results are expected in 1Q 2028. Company also noted prior positive Phase 2 schizophrenia results and a Phase 3 schizophrenia program on track with H2 2027 results expected.
LB Pharmaceuticals (Nasdaq: LBRX) announced on January 21, 2026 the appointment of Dr. Minako Pazdera as General Counsel. Dr. Pazdera brings more than 25 years of experience in corporate governance, intellectual property, strategic transactions and compliance and will support advancement of LB-102 and the company’s CNS-focused strategy. Her background includes GC roles at Kardigan and Carmot Therapeutics, where she led legal work during a dual-track process that culminated in Carmot’s acquisition by Roche for up to $3.1 billion in 2024. She holds a J.D., a Ph.D. in biological sciences and a B.A. in molecular and cell biology.
LB Pharmaceuticals (Nasdaq: LBRX) granted inducement equity awards to two new senior hires on January 9, 2026 under the Nasdaq Listing Rule 5635(c)(4). The company awarded Ellen Rose options to purchase 100,000 shares and Lindsay Beaupre options to purchase 75,000 shares.
The options have a 10-year term, an exercise price of $20.73 per share (the closing price on the grant date), and vest over 4 years with 25% vesting after one year and the remainder vesting monthly in 1/48th increments, subject to continuous service.
LB Pharmaceuticals (Nasdaq: LBRX) announced on January 6, 2026 the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture.
Management additions arrive as the company advances LB-102 into pivotal development for schizophrenia and a Phase 2 trial in bipolar depression. Ms. Rose brings communications, investor relations, patient advocacy, and government affairs experience from Lyell Immunopharma, Prothena, and Johnson & Johnson. Ms. Beaupre brings people and operations leadership experience from Lyndra Therapeutics, Vertex, Immunogen, State Street, and Fidelity.
LB Pharmaceuticals (Nasdaq: LBRX) announced an inducement equity award to its new Chief Commercial Officer, Kaya Pai Panandiker, granted on December 10, 2025 under the Nasdaq Listing Rule 5635(c)(4) exception. The award is an option to purchase 195,000 shares of common stock with a 10-year term and an exercise price of $21.36 per share (closing price on the grant date). The option vests over 4 years: 25% on the first anniversary and the remaining shares in equal monthly installments (1/48th) thereafter, subject to continuous service.
LB Pharmaceuticals (Nasdaq: LBRX) announced it will be added to the Russell 2000 and Russell 3000 indices, effective at the open of U.S. markets on December 22, 2025, as part of the 2025 Russell reconstitution. The company said this follows its recent IPO and comes as it is approaching initiation of key clinical trials for LB-102 in schizophrenia and bipolar depression. The Russell reconstitution ranks the 4,000 largest U.S. stocks by market capitalization as of April 30. The release notes about $10.6 trillion benchmarked to Russell US indexes (June 2024) and $18.1 trillion benchmarked to FTSE Russell indexes.